Antenatal allopurinol for reduction of birth asphyxia induced brain damage (ALLO-Trial); a randomized double blind placebo controlled multicenter study

Joepe J Kaandorp, Manon J N L Benders, Carin M A Rademaker, Helen L Torrance, Martijn A Oudijk, Timo R de Haan, Kitty W M Bloemenkamp, Monique Rijken, Maria G van Pampus, Arie F Bos, Martina M Porath, Sidarto Bambang Oetomo, Christine Willekes, A W Danilo Gavilanes, Maurice G A J Wouters, Ruurd M van Elburg, Anjoke J M Huisjes, Saskia C M J E R Bakker, Claudia A van Meir, Jeannette von Lindern, Janine Boon, Inge P de Boer, Robbert Jp Rijnders, Corrie J W F M Jacobs, Cuno S P M Uiterwaal, Ben Willem J Mol, Gerard H A Visser, Frank van Bel, Jan B Derks, Joepe J Kaandorp, Manon J N L Benders, Carin M A Rademaker, Helen L Torrance, Martijn A Oudijk, Timo R de Haan, Kitty W M Bloemenkamp, Monique Rijken, Maria G van Pampus, Arie F Bos, Martina M Porath, Sidarto Bambang Oetomo, Christine Willekes, A W Danilo Gavilanes, Maurice G A J Wouters, Ruurd M van Elburg, Anjoke J M Huisjes, Saskia C M J E R Bakker, Claudia A van Meir, Jeannette von Lindern, Janine Boon, Inge P de Boer, Robbert Jp Rijnders, Corrie J W F M Jacobs, Cuno S P M Uiterwaal, Ben Willem J Mol, Gerard H A Visser, Frank van Bel, Jan B Derks

Abstract

Background: Hypoxic-ischaemic encephalopathy is associated with development of cerebral palsy and cognitive disability later in life and is therefore one of the fundamental problems in perinatal medicine. The xanthine-oxidase inhibitor allopurinol reduces the formation of free radicals, thereby limiting the amount of hypoxia-reperfusion damage. In case of suspected intra-uterine hypoxia, both animal and human studies suggest that maternal administration of allopurinol immediately prior to delivery reduces hypoxic-ischaemic encephalopathy.

Methods/design: The proposed trial is a randomized double blind placebo controlled multicenter study in pregnant women at term in whom the foetus is suspected of intra-uterine hypoxia.Allopurinol 500 mg IV or placebo will be administered antenatally to the pregnant woman when foetal hypoxia is suspected. Foetal distress is being diagnosed by the clinician as an abnormal or non-reassuring foetal heart rate trace, preferably accompanied by either significant ST-wave abnormalities (as detected by the STAN-monitor) or an abnormal foetal blood scalp sampling (pH < 7.20).Primary outcome measures are the amount of S100B (a marker for brain tissue damage) and the severity of oxidative stress (measured by isoprostane, neuroprostane, non protein bound iron and hypoxanthine), both measured in umbilical cord blood. Secondary outcome measures are neonatal mortality, serious composite neonatal morbidity and long-term neurological outcome. Furthermore pharmacokinetics and pharmacodynamics will be investigated.We expect an inclusion of 220 patients (110 per group) to be feasible in an inclusion period of two years. Given a suspected mean value of S100B of 1.05 ug/L (SD 0.37 ug/L) in the placebo group this trial has a power of 90% (alpha 0.05) to detect a mean value of S100B of 0.89 ug/L (SD 0.37 ug/L) in the 'allopurinol-treated' group (z-test2-sided). Analysis will be by intention to treat and it allows for one interim analysis.

Discussion: In this trial we aim to answer the question whether antenatal allopurinol administration reduces hypoxic-ischaemic encephalopathy in neonates exposed to foetal hypoxia.

Trial registration number: Clinical Trials, protocol registration system: NCT00189007.

Figures

Figure 1
Figure 1
Flowchart ALLO-trial.

References

    1. Fellman V, Raivio KO. Reperfusion injury as the mechanism of brain damage after perinatal asphyxia. Pediatr Res. 1997;41:599–606. doi: 10.1203/00006450-199705000-00001.
    1. Rosenberg AA, Murdaugh E, White CW. The role of oxygen free radicals in postasphyxia cerebral hypoperfusion in newborn lambs. Pediatr Res. 1989;26:215–219. doi: 10.1203/00006450-198909000-00012.
    1. Warner DS, Sheng H, Batinic-Haberle I. Oxidants, antioxidants and the ischemic brain. J Exp Biol. 2004;207:3221–3231. doi: 10.1242/jeb.01022.
    1. Palmer C, Vannucci RC, Towfighi J. Reduction of perinatal hypoxic-ischemic brain damage with allopurinol. Pediatr Res. 1990;27:332–336. doi: 10.1203/00006450-199004000-00003.
    1. Whitelaw A. Systematic review of therapy after hypoxic-ischaemic brain injury in the perinatal period. Semin Neonatol. 2000;5:33–40. doi: 10.1053/siny.1999.0113.
    1. Peeters-Scholte C, Braun K, Koster J, Kops N, Blomgren K, Buonocore G, van Buul-Offers S, Hagberg H, Nicolay K, van Bel F, Groenendaal F. Effects of allopurinol and deferoxamine on reperfusion injury of the brain in newborn piglets after neonatal hypoxia-ischemia. Pediatr Res. 2003;54:516–522. doi: 10.1203/01.PDR.0000081297.53793.C6.
    1. Van Bel F, Shadid M, Moison RM, Dorrepaal CA, Fontijn J, Monteiro L, van de Bor, Berger HM. Effect of allopurinol on postasphyxial free radical formation, cerebral hemodynamics, and electrical brain activity. Pediatrics. 1998;101:185–193. doi: 10.1542/peds.101.2.185.
    1. Gunes T, Ozturk MA, Koklu E, Kose K, Gunes I. Effect of allopurinol supplementation on nitric oxide levels in asphyxiated newborns. Pediatr Neurol. 2007;36:17–24. doi: 10.1016/j.pediatrneurol.2006.08.005.
    1. Benders MJ, Bos AF, Rademaker CM, Rijken M, Torrance HL, Groenendaal F, van Bel F. Early postnatal allopurinol does not improve short term outcome after severe birth asphyxia. Arch Dis Child Fetal Neonatal Ed. 2006;91:163–165. doi: 10.1136/adc.2005.086652.
    1. Gluckman PD, Wyatt JS, Azzopardi D, Ballard R, Edwards AD, Ferriero DM, Polin RA, Robertson CM, Thoresen M, Whitelaw A, Gunn AJ. Selective head cooling with mild systemic hypothermia after neonatal encephalopathy: multicentre randomised trial. Lancet. 2005;365:663–670.
    1. Boda D, Németh P, Kiss P, Orvos H. Treatment of mothers with allopurinol to produce therapeutic blood levels in newborns. Prenat Neonat Med. 1999;4:130–134.
    1. van Dijk AJ, Parvizi N, Taverne MA, Fink-Gremmels J. Placental transfer and pharmacokinetics of allopurinol in late pregnant sows and their fetuses. J Vet Pharmacol Ther. 2008;31:489–495. doi: 10.1111/j.1365-2885.2008.00976.x.
    1. Derks JB, Oudijk MA, Rosén KG, Thakor AS, Visser GHA, van Bel F, Giussani DA. Allopurinol maintains umbilical blood flow following repeated episodes of ischaemia-reperfusion in fetal sheep during late gestation [abstract] J Soc Gynecol Invest. 2006;13:s35.
    1. Masaoka N, Nakajima Y, Hayakawa Y, Ohgame S, Hamano S, Nagaishi M, Yamamoto T. Transplacental effects of allopurinol on suppression of oxygen free radical production in chronically instrumented fetal lamb brains during intermittent umbilical cord occlusion. J Matern Fetal Neonatal Med. 2005;18:1–7. doi: 10.1080/14767050500127716.
    1. Torrance HL, Benders MJ, Derks JB, Rademaker CM, Bos AF, Berg P Van Den, Longini M, Buonocore G, Venegas M, Baquero H, Visser GH, Van Bel F. Maternal allopurinol during fetal hypoxia lowers cord blood levels of the brain injury marker S-100B. Pediatrics. 2009;124:350–357. doi: 10.1542/peds.2008-2228.
    1. Torrance H, Derks JB, Oudijk MA, Thakor AS, Cindrova-Davies T, van Bel F, Visser GHA, Burton GJ, Giussani DA. Maternal treatment with allopurinol diminishes fetal cardiac oxidative stress following repeated episodes of ischaemia-reperfusion in sheep. Proceedings of the 34th annual meeting of the Fetal and Neonatal Physiological Society; 26-29 august 2007, Sendai, Japan. 2007. p. 90.
    1. Ferriero DM. Neonatal brain injury. N Engl J Med. 2004;351:1985–1995. doi: 10.1056/NEJMra041996.
    1. Hagberg B, Hagberg G, Olow I. The changing panorama of cerebral palsy in Sweden. VI. Prevalence and origin during the birth year period 1983-1986. Acta Paediatr. 1993;82:387–393. doi: 10.1111/j.1651-2227.1993.tb12704.x.
    1. van Handel M, Swaab H, de Vries LS, Jongmans MJ. Long-term cognitive and behavioral consequences of neonatal encephalopathy following perinatal asphyxia: a review. Eur J Pediatr. 2007;166:645–654. doi: 10.1007/s00431-007-0437-8.
    1. Summary of Product Characteristics Acepurin®.
    1. Halevy S, Ghislain PD, Mockenhaupt M, Fagot JP, Bouwes Bavinck JN, Sidoroff A, Naldi L, Dunant A, Viboud C, Roujeau JC. EuroSCAR Study Group. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol. 2008;58:25–32. doi: 10.1016/j.jaad.2007.08.036.
    1. Chaudhari T, McGuire W. Allopurinol for preventing mortality and morbidity in newborn infants with suspected hypoxic-ischaemic encephalopathy. Cochrane Database Syst Rev. 2008;16(2):CD006817.
    1. van Kesteren C, Benders MJ, Groenendaal F, van Bel F, Ververs FF, Rademaker CM. Population pharmacokinetics of allopurinol in full-term neonates with perinatal asphyxia. Ther Drug Monit. 2006;28:339–344. doi: 10.1097/01.ftd.0000211808.74192.86.
    1. Sarnat HB, Sarnat MS. Neonatal encephalopathy following fetal distress. A clinical and electroencephalographic study. Arch Neurol. 1976;33:696–705.
    1. Thompson CM, Puterman AS, Linley LL, Hann FM, Elst CW van der, Molteno CD, Malan AF. The value of a scoring system for hypoxic ischaemic encephalopathy in predicting neurodevelopmental outcome. Acta Paediatr. 1997;86:757–761. doi: 10.1111/j.1651-2227.1997.tb08581.x.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere